Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen
07 Luglio 2014 - 4:23PM
Company Announcement
- Genmab to receive USD 25 million milestone payment from
Janssen
- Milestone triggered by progress in the Phase III study
of daratumumab in combination with lenalidomide and dexamethasone
in relapsed or refractory multiple myeloma
Genmab A/S (Copenhagen:GEN) announced
today it has reached the third
milestone in its daratumumab collaboration with Janssen
Biotech, Inc. ("Janssen"). The USD 25 million milestone
payment was triggered by progress in the ongoing Phase III study of
daratumumab in combination with lenalidomide and dexamethasone
versus lenalidomide and dexamethasone alone for the treatment of
relapsed or refractory multiple myeloma.
"Since our partnership with Janssen began in October 2012, we
have made very significant progress with the development of
daratumumab, announcing five new clinical studies and reporting
data from two ongoing studies in multiple myeloma. Today's
milestone marks another important step, as patients are now
receiving treatment in the first Phase III study of daratumumab in
multiple myeloma," said Jan van de Winkel, Ph.D., Chief Executive
Officer of Genmab.
The milestone payment is included in Genmab's 2014 financial
guidance published on May 1, 2014.
About daratumumab
Daratumumab is a human CD38 monoclonal antibody with
broad-spectrum killing activity. Daratumumab is in clinical
development for multiple myeloma (MM). Daratumumab targets the CD38
molecule which is highly expressed on the surface of multiple
myeloma cells. Daratumumab may also have potential in other cancers
on which CD38 is expressed, including diffuse large B-cell
lymphoma, chronic lymphocytic leukemia, acute lymphoblastic
leukemia, plasma cell leukemia, acute myeloid leukemia, follicular
lymphoma and mantle cell lymphoma. Daratumumab has been granted
Breakthrough Therapy Designation from the US FDA for the treatment
of patients with multiple myeloma who have received at least three
prior lines of therapy including a proteasome inhibitor (PI) and an
immunomodulatory agent (IMiD) or who are double refractory to a PI
and an IMiD. In August 2012, Genmab granted Janssen Biotech,
Inc. an exclusive worldwide license to develop and commercialize
daratumumab.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company
specializing in the creation and development of differentiated
human antibody therapeutics for the treatment of cancer.
Founded in 1999, the company currently has one marketed antibody,
Arzerra(r) (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications, a clinical pipeline with both
late and early stage programs, and an innovative pre-clinical
pipeline. Genmab's technology base consists of validated and
proprietary next generation antibody technologies - the DuoBody(r)
platform for generation of bispecific antibodies, and the
HexaBody(tm) platform which creates effector function enhanced
antibodies. Genmab's deep antibody expertise is expected to provide
a stream of future product candidates. Partnering of selected
innovative product candidates and technologies is a key focus of
Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more
information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor
Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62
60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products obsolete, and other factors. For a further discussion of
these risks, please refer to the risk management sections in
Genmab's most recent financial reports, which are available on
www.genmab.com . Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement
nor to confirm such statements in relation to actual results,
unless required by law.
Genmab A/S and its subsidiaries own the following trademarks:
Genmab(r); the Y-shaped Genmab logo(r); Genmab in combination with
the Y-shaped Genmab logo(tm); the DuoBody logo(tm); the HexaBody
logo(tm); HuMax(r); HuMax-CD20(r); DuoBody(r); HexaBody(tm) and
UniBody(r). Arzerra(r) is a registered trademark of the GSK group
of companies.
Company Announcement no. 34 CVR no. 2102 3884
Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark
Grafico Azioni Genmab A S (PK) (USOTC:GNMSF)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Genmab A S (PK) (USOTC:GNMSF)
Storico
Da Nov 2023 a Nov 2024